Clinical Trials Browser

Phase 1/2 × INDUSTRY × Carmustine × Clear all

NCT03382977 2025-03-11

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Phase 1/2 Recruiting

Glioblastoma, Neoplasms

NCT04421378 2024-12-16

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma

Phase 1/2 Terminated

74 enrolled 23 charts

Glioblastoma